Client News

OKYO Pharma Limited: Change of Auditor
Home / Client News / OKYO Pharma Limited: Change of Auditor

London and New York, N.Y., 1 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market,  announces that the board of directors of the Company (the “Board” or “Directors”), has appointed PKF Littlejohn LLP (“PKF”) as its new independent auditor with immediate effect.


If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.


Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This